<DOC>
	<DOCNO>NCT00608959</DOCNO>
	<brief_summary>The purpose research study determine omiganan 1 % gel ( investigational medication research study ) effective safe compare chlorhexidine 2 % ( FDA approve medication ) kill bacteria ( germ ) live surface skin . Both study medication apply topically ( surface skin ) .</brief_summary>
	<brief_title>Study Antimicrobial Activity Omiganan 1 % Gel vs. Chlorhexidine 2 % Topical Skin Antisepsis Healthy Adult Subjects</brief_title>
	<detailed_description>The study comprise 2 part approximately 20 subject participate part . Subjects eligible Part 1 omiganan 1 % gel apply 6 site across chest and/or abdomen chlorhexidine 2 % solution apply 6 match site contralateral side . Subjects eligible Part 2 omiganan 1 % gel apply 6 site across upper chest abdomen.In addition , subject Part 2 2 peripheral catheter insert , one arm.One catheter insertion site treat omiganan 1 % gel ( follow treatment isopropyl alcohol ) site treat chlorhexidine 2 % /isopropyl alcohol .</detailed_description>
	<mesh_term>Chlorhexidine gluconate</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<mesh_term>Chlorhexidine</mesh_term>
	<criteria>Male female subjects1870 year age No evidence dermatosis , dermatitis , inflammation , scar , acute injury drug application sit chest abdomen Subjects must screen sample skin right leave side chest abdomen contain least 2.5 log10 colony form unit per square centimeter ( CFU/cm2 ) organism ( average 2 sample obtain screen ) Willing provide write informed consent . Allergies sensitivities alcohol , adhesive tape , bandage , latex , chlorhexidine gluconate , ingredient omiganan 1 % gel Prior treatment systemic antibiotic , product know affect normal microbial flora skin within 7 day screen examination Requirement topical antibiotic use within 10 cm study test site Subjects treat investigational drug ( omiganan ) within previous 30 day , participate investigational drug study time course study Subjects previously treat omiganan experience possibly related adverse event study Note : wash period one week require prior participation Part 2 study A medical condition Investigator believe may interfere safety subject intent conduct study Note : include condition : severe eczema , psoriasis and/or dermal infection , old scar , insulin dependent diabetes mellitus , severe immunocompromising condition , HIV infection , use medication would interfere assessment study endpoints A current recent history illicit drug alcohol abuse Subjects willing able fulfill protocol requirement Pregnancy . Women childbearing potential positive equivocal result urine and/or blood pregnancy test study enrollment include</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Skin colonization</keyword>
	<keyword>Catheter colonization</keyword>
	<keyword>Catheter site infection</keyword>
</DOC>